Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411044 | 1.00 | ACHE (0.50) | ACHECA1CA2CA7CA9 | |
| Lithium Ion SCHEMBL4449956 | 0.89 | ACHE (0.41) | ACHECA1CA2CA7CA9 | |
| SCHEMBL635049 | 0.79 | ABL1 (0.58) | ALDH1A1CYP3A4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9457403 | 0.79 | MAOB (0.36) | CYP3A4MAOB | |
| SCHEMBL1794814 | 0.78 | ACHE (0.50) | ACHECA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL8086769 | 0.78 | ACHE (0.50) | ACHECA1CA2CA7CA9 | |
| SCHEMBL3138349 | 0.78 | TP53 (0.53) | ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL635453 | 0.78 | RXRA (0.42) | CA2ALDH1A1NPC1RAB9ARELA | |
| SCHEMBL7265757 | 0.77 | LTA4H (0.50) | ALDH1A1SMN1; SMN2MAOB | |
| Bromide SCHEMBL10653968 | 0.77 | ACHE (0.48) | ACHECA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 949 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| CN-119060007-A | Preparation and application of fluorescence donor capable of controllably releasing hydrogen sulfide and carbon monoxide | 广西中医药大学 | 2024-12-03 | — | — | CN | claimed |
| CN-115260043-B | Synthesis method of meta-hydroxylamine bitartrate | 海南长春花药业有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-115701422-B | Preparation method of KGP94 | 中国科学院昆明植物研究所 | 2024-02-09 | — | — | CN | claimed |
| CN-114436790-B | Synthesis method of 6-methoxy-1-tetralone | 浙江仙居君业药业有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115701422-A | Preparation method of KGP94 | 中国科学院昆明植物研究所 | 2023-02-10 | — | — | CN | claimed |
| CN-115260043-A | Synthesis method of meta-hydroxylamine bitartrate | 海南长春花药业有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-114436790-A | Synthesis method of 6-methoxy-1-tetralone | 浙江仙居君业药业有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-101265201-B | Method for synthesizing tramadol hydrochloride | UNIV ZHEJIANG TECHNOLOGY | 2011-11-23 | — | — | CN | claimed |
| CN-100548950-C | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2009-10-14 | — | — | CN | claimed |
| US-20070112074-A1 | Tramadol recovery process | IPCA LABORATORIES LIMITED (IN) | 2007-05-17 | — | — | US | claimed |
| EP-1785412-A1 | Tramadol recovery process | IPCA Laboratories Limited (IN) | 2007-05-16 | — | — | EP | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| CN-1759084-A | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2006-04-12 | — | — | CN | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| EP-0778262-B1 | Process for the purification of (RR-SS)-2-dimethyl-aminomethyl-1-(3-methoxyphenyl)cyclohexanol and its salts | CHEMAGIS LTD (IL) | 2001-01-24 | — | — | EP | claimed |
| US-5672755-A | Process for the purification of (RR-SS)-2-dimethyl-aminomethyl-1-(3-methoxyphenyl)cyclohexanol and its salts | CHEMAGIS LTD. (IL) | 1997-09-30 | — | — | US | claimed |
| EP-0778262-A2 | Process for the purification of (RR-SS)-2-dimethyl-aminomethyl-1-(3-methoxyphenyl)cyclohexanol and its salts | Chemagis Ltd. (IL) | 1997-06-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112074-A1 | Tramadol recovery process | TRAM1, OPRK1, SLC6A6 | ACHE 894/4885CA1 2464/4885CA2 1115/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | ACHE 4145/4885CA1 2271/4885CA2 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.